Plastic waste is typically viewed as an environmental burden, contributing to pollution and the spread of microplastics. However, researchers at the University of Edinburgh are exploring a radically different perspective: using plastic as a raw material for medicine. In a study the team demonstrates how discarded plastic can be transformed into levodopa, a key drug used in the treatment of Parkinson’s disease.
By engineering E. coli bacteria, the researchers were able to convert polyethylene terephthalate (PET), a common plastic used in bottles and packaging, into levodopa. This biotechnological approach offers a potential alternative to conventional production methods, which rely on fossil fuel–based chemical processes that are energy-intensive and carbon-heavy.
Addressing rising demand
Parkinson’s disease affects more than 10 million people worldwide, with prevalence expected to increase as populations age. Levodopa remains the most effective therapy for managing symptoms such as tremors and muscle stiffness, making sustainable production methods increasingly relevant.
The Edinburgh study builds on earlier work in which the same team successfully converted plastic into paracetamol. These findings support a broader shift toward using waste materials as chemical feedstocks, reducing reliance on fossil resources while addressing environmental challenges.
Parallel research efforts, including work by the University of Southern California and the University of St Andrews, have shown that plastics can also be broken down into building blocks for antibiotics, cancer therapies and other pharmaceuticals. Together, these developments highlight the emerging potential of “circular chemistry” in healthcare innovation. The studyb was recently published in Nature Sustainability.
A sustainable pharmaceutical chain
The concept of converting plastic waste into medicines aligns with broader efforts to create a circular economy, where materials are reused rather than discarded. By unlocking the carbon embedded in plastics, researchers aim to reduce both environmental impact and dependence on fossil fuels.
However, significant challenges remain before the technology can be applied at scale. Industrial production processes must be optimized, and strict regulatory standards must be met to ensure safety and efficacy. In addition, sourcing sufficient and suitable plastic waste presents logistical and economic hurdles.
Despite these challenges, the research provides a glimpse into a future where biotechnology and materials science converge to address both environmental and healthcare needs. While still in an early stage, the approach could eventually contribute to more sustainable pharmaceutical manufacturing and improved access to essential medicines. As the field evolves, collaboration between scientists, industry and policymakers will be essential to translate these laboratory breakthroughs into real-world impact.
Light therapy
Last year we wrote about another Parkinson treatment innovation where research suggested that light therapy may significantly improve symptoms of Parkinson’s disease, particularly when combined with exercise. The 72-week randomized study involved 59 patients with moderate Parkinson’s.
Participants receiving active light therapy targeting the gut-brain axis showed sustained improvements in mobility, motor function, daily activities, and anxiety compared to those who discontinued treatment. For example, mobility improved by 14% in the treatment group, while declining in others. The therapy, delivered via devices from SYMBYX, focuses on the gut-brain connection, increasingly recognized in Parkinson’s progression.
